Skip to main content
Search
Main content
Molecular therapy : the journal of the American Society of Gene Therapy
Published

Schwann cell targeted gene delivery in peripheral neuropathy models and non-human primates

Authors

Natasa Schiza, Andria Lytridou, Maria Xinari, Wenjing Xu, John D Graef, Irene Sargiannidou, Christina Tryfonos, Jan Richter, Amanda Heslegrave, Henrik Zetterberg, Alexia Kagiava, Kleopas A Kleopa

Abstract

Mol Ther. 2026 Nov 21:S1525-0016(26)00977-9. doi: 10.1016/j.ymthe.2026.11.035. Online ahead of print.

ABSTRACT

Gene therapy using recombinant adeno-associated viral (rAAV) vectors is a promising strategy for treating inherited demyelinating neuropathies such as Charcot-Marie-Tooth disease type 1X (CMT1X). Efficient and safe targeting of myelinating Schwann cells remains a key challenge for clinical translation. Here, we evaluated the safety, efficacy and scale-up potential of Schwann cell targeting by clinically relevant rAAVrh10 and rAAVrh74 vectors following lumbar intrathecal delivery in CMT1X mice and non-human primates (NHPs). Both rAAVrh10 and rAAVrh74 achieved efficient, dose-dependent biodistribution to the peripheral nerves with expression in Schwann cells driven by cell-specific promoter. In the Gjb1-null CMT1X mouse model, delivery of the therapeutic human GJB1 gene led to significant functional and morphological improvements, including increased grip strength, faster nerve conduction velocities, improved myelination and decreased inflammation. In NHPs, both serotypes demonstrated robust PNS biodistribution and Schwann cell targeting without adverse neurological effects, or liver toxicity related to therapeutic vectors. Overall, a single lumbar intrathecal injection of rAAVrh10 or rAAVrh74 enables efficient, dose-dependent Schwann cell transduction and therapeutic gene expression with functional benefit in the Gjb1- null demyelinating neuropathy mouse model, without toxicity in NHPs. This study supports the clinical translation of rAAV-mediated gene therapy targeting Schwann cells for treating CMT1X.

PMID:43065200 | DOI:10.1016/j.ymthe.2026.11.035

UK DRI Authors

Dr Amanda Heslegrave

Principal Research Fellow

Co-leading the UK DRI Biomarker Factory platform based at UK DRI at UCL

Dr Amanda Heslegrave

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg